Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 7/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875242 | 0.80 | TDP1 (0.48) | STK17BSTK17ABRD4TDP1DRD2 | |
| SCHEMBL585025 | 0.76 | ALDH1A1 (0.41) | STK17BSTK17AMEN1GAAKMT2A | |
| SCHEMBL2878564 | 0.76 | DRD2 (0.42) | STK17BSTK17ABRD4TDP1DRD2 | |
| SCHEMBL18764883 | 0.75 | ALDH1A1 (0.51) | STK17BSTK17AMEN1GAAKMT2A | |
| SCHEMBL2878422 | 0.75 | ALDH1A1 (0.50) | STK17BSTK17AKMT2ABRD4 | |
| SCHEMBL30875239 | 0.73 | TDP1 (0.41) | STK17BSTK17ABRD4TDP1DRD2 | |
| SCHEMBL345147 | 0.72 | TDP1 (0.44) | STK17BSTK17AMEN1GAAKMT2A | |
| SCHEMBL7963556 | 0.72 | CAMK2D (0.46) | MEN1GAAKMT2ATDP1CAMK2D | |
| SCHEMBL20140741 | 0.72 | L3MBTL1 (0.52) | STK17BSTK17AMEN1GAAKMT2A | |
| SCHEMBL29175237 | 0.71 | MEN1 (0.42) | STK17BSTK17AMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | STK17B 682/4885STK17A 587/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.